AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|
30.9 C
New York
Monday, June 29, 2026

Tag: countries

JCDecaux wins the exclusive advertising concession for Brussels Airport

JCDecaux wins the exclusive advertising concession for Brussels Airport 

Amundi: First half and second quarter 2025 results

Amundi: First half and second quarter 2025 results

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

New ETC report demonstrates that wind and solar-dominant power systems are competitive, reliable, and technically and economically feasible

LONDON, July 29, 2025 /PRNewswire/ -- The Energy Transitions Commission (ETC) has today published a landmark report, Power Systems Transformation: Delivering Competitive, Resilient Electricity...

New ETC report demonstrates that wind and solar-dominant power systems are competitive, reliable, and technically and economically feasible

LONDON, July 29, 2025 /PRNewswire/ -- The Energy Transitions Commission (ETC) has today published a landmark report, Power Systems Transformation: Delivering Competitive, Resilient Electricity...

Weatherford Awarded Managed Pressure Drilling Contract for Woodside Energy’s Trion Deepwater Development

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- Weatherford International plc (NASDAQ: WFRD) ("Weatherford" or the "Company") today announced it has been awarded a significant contract to deliver Managed Pressure Drilling (MPD) services for the Trion project, a deepwater oil production project in Mexico operated by Woodside Petróleo Operaciones de México, S. de R.L. de C.V.

PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on...

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

Piramal Pharma Limited Announces Results for Q1FY26

MUMBAI, India, July 28, 2025 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, and health and wellness company, today...

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

Europcar Mobility Group Chooses OpenText to Deliver Global E-Invoicing Compliance

WATERLOO, ON, July 28, 2025 /PRNewswire/ -- Europcar Mobility Group is a leader in global mobility services leader with more than 75 years of...

Europcar Mobility Group Chooses OpenText to Deliver Global E-Invoicing Compliance

WATERLOO, ON, July 28, 2025 /CNW/ -- Europcar Mobility Group is a leader in global mobility services leader with more than 75 years of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCountries